Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Safety and Efficacy of Tocolytics for the Treatment of Spontaneous Preterm Labour

Author(s): Ronald F. Lamont* and Jan S. Jørgensen

Volume 25, Issue 5, 2019

Page: [577 - 592] Pages: 16

DOI: 10.2174/1381612825666190329124214

Price: $65

Abstract

Background: Preterm birth is the major cause of perinatal mortality and morbidity worldwide. Attempts to reduce the burden may be proactive using biochemical or biophysical prediction and preventative measures. If these efforts fail, then the approach may have to be reactive using tocolytics to inhibit spontaneous preterm labour.

Objective: We have reviewed the evidence concerning the safety and efficacy of various classes of tocolytic agents.

Results: The evidence to support the use of magnesium sulfate or nitric oxide donors as a tocolytic is poor. Compared to placebo or no treatment, there is evidence to support the efficacy of calcium channel blockers (mainly nifedipine), prostaglandin synthetase inhibitors (mainly indomethacin and sulindac), oxytocin receptor antagonists (mainly atosiban) and β2-agonists (mainly ritodrine, terbutaline, salbutamol and fenoterol). Maternal safety concerns have reduced the use of β2-agonists. Fetal safety and gestational age restrictions have largely condemned prostaglandin synthetase inhibitors to second-line therapy. First-line therapy in Europe and other parts of the world outside the USA and Australia is limited to calcium channel blockers and oxytocin receptor antagonists. With respect to efficacy, atosiban and nifedipine are similar, but the robustness of the evidence favours atosiban. With respect to safety, atosiban is clearly the safest tocolytic as there are fetomaternal concerns with nifedipine, particularly in high daily doses.

Conclusion: The perfect tocolytic that is uniformly effective and safe does not exist. Cost, licensing and informed consent are considerations involved in the choice. Efforts continue to develop and introduce other or better agents, including novel compounds such as progesterone, PGF2α antagonists and statins.

Keywords: Beta-agonists, calcium channel blockers, efficacy, oxytocin receptor antagonists, prostaglandin synthetase inhibitors, safety, tocolytics.

« Previous Next »
[1]
March of Dimes F. March of Dimes White Paper on Preterm Birth: the Global and Regional Toll 2009.https://www.marchofdimes.org/materials/white-paper-on-preterm-birth.pdf
[2]
Fellman V, Hellstrom-Westas L, Norman M, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301(21): 2225-33.
[3]
Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106(4): 659-71.
[4]
Preterm Birth. Causes, Consequences, and Prevention Behrman RE, Butler AS, Eds. 2007.
[5]
Petrou S, Abangma G, Johnson S, Wolke D, Marlow N. Costs and health utilities associated with extremely preterm birth: Evidence from the EPICure study. Value Health 2009; 12(8): 1124-34.
[6]
Campbell S. Prevention of spontaneous preterm birth: Universal cervical length assessment and vaginal progesterone in women with a short cervix: time for action! Am J Obstet Gynecol 2018; 218(2): 151-8.
[7]
Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: A meta-analysis of individual patient data. Am J Obstet Gynecol 2018; 218(2): 161-80.
[8]
Alston MJ, Alexandrovic K, Stiglich N, Metz TD. Discontinuation of Tocolytics for Preterm Labor in an Academic Safety Net Hospital: Impact on the Duration of Betamethasone Exposure. J Reprod Med 2016; 61(3-4): 109-13.
[9]
Nazifovic E, Husslein H, Lakovschek I, et al. Differences between evidence-based recommendations and actual clinical practice regarding tocolysis: A prospective multicenter registry study. BMC Pregnancy Childbirth 2018; 18(1): 446.
[10]
King JF, Grant A, Keirse MJ, Chalmers I. Beta-mimetics in preterm labour: An overview of the randomized controlled trials. Br J Obstet Gynaecol 1988; 95(3): 211-22.
[11]
Finnstrom O, Olausson PO, Sedin G, et al. The Swedish national prospective study on extremely low birthweight (ELBW) infants. Incidence, mortality, morbidity and survival in relation to level of care. Acta Paediatr 1997; 86(5): 503-11.
[12]
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454.
[13]
Lamont RF, Dunlop PD, Crowley P, Levene MI, Elder MG. Comparative mortality and morbidity of infants transferred in utero or postnatally. J Perinat Med 1983; 11(4): 200-3.
[14]
Klauser CK, Briery CM, Tucker AR, et al. Tocolysis in women with advanced preterm labor: A secondary analysis of a randomized clinical trial The journal of maternal-fetal & neonatal medicine : The official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2016; 29(5): 696-700.
[15]
Spellacy WN, Cruz AC, Birk SA, Buhi WC. Treatment of premature labor with ritodrine: A randomized controlled study. Obstet Gynecol 1979; 54(2): 220-3.
[16]
Besinger REIT. Tocolytic Therapy. Preterm Labor 1997; pp. 243-97.
[17]
Treatment of preterm labor with the beta-adrenergic agonist ritodrine. The Canadian Preterm Labor Investigators Group. N Engl J Med 1992; 327(5): 308-12.
[18]
Leveno KJ, Cunningham FG. Beta-adrenergic agonists for preterm labor. N Engl J Med 1992; 327(5): 349-51.
[19]
Lamont RF. The pathophysiology of pulmonary oedema with the use of beta-agonists. BJOG 2000; 107(4): 439-44.
[20]
Tocolytic drugs for women in preterm labour Royal College of Obstetricians and Gynaecologists 2002.
[21]
Lyndrup J, Lamont RF. The choice of a tocolytic for the treatment of preterm labor: A critical evaluation of nifedipine versus atosiban. Expert Opin Investig Drugs 2007; 16(6): 843-53.
[22]
Lamont RF. The development and introduction of anti-oxytocic tocolytics. BJOG 2003; 110(Suppl. 20): 108-12.
[23]
Boos J. Off label use--label off use? Ann Oncol 2003; 14(1): 1-5.
[24]
Lamont CD, Jorgensen JS, Lamont RF. The safety of tocolytics used for the inhibition of preterm labour. Expert Opin Drug Saf 2016; 15(9): 1163-73.
[25]
Guiet-Bara A, Bara M, Durlach J. Comparative study of the effects of two tocolytic agents (magnesium sulfate and alcohol) on the ionic transfer through the isolated human amnion. Eur J Obstet Gynecol Reprod Biol 1985; 20(5): 297-304.
[26]
Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002; (4): CD001060.
[27]
Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: A systematic review. Obstet Gynecol 1999; 94(5 Pt 2): 869-77.
[28]
Grimes DA, Nanda K. Magnesium sulfate tocolysis: Time to quit. Obstet Gynecol 2006; 108(4): 986-9.
[29]
Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (1): CD004661.
[30]
Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (5): CD000940.
[31]
Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: A systematic review. BMC Pregnancy Childbirth 2013; 13: 195.
[32]
Wilson MS, Ingersoll M, Meschter E, Bodea-Braescu AV, Edwards RK. Evaluating the side effects of treatment for preterm labor in a center that uses “high-dose” magnesium sulfate. Am J Perinatol 2014; 31(8): 711-6.
[33]
Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997; 350(9090): 1517-8.
[34]
Mittendorf R, Covert R, Elin R, Pryde PG, Khoshnood B, Lee K. Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstet Gynecol 2001; 98(1): 75-8.
[35]
Mittendorf R, Dambrosia J, Dammann O, et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. J Pediatr 2002; 140(5): 540-6.
[36]
McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour. Cochrane Database Syst Rev 2015; (12): CD011200.
[37]
Natuzzi ES, Ursell PC, Harrison M, Buscher C, Riemer RK. Nitric oxide synthase activity in the pregnant uterus decreases at parturition. Biochem Biophys Res Commun 1993; 194(1): 1-8.
[38]
Riemer RK, Buscher C, Bansal RK, Black SM, He Y, Natuzzi ES. Increased expression of nitric oxide synthase in the myometrium of the pregnant rat uterus. Am J Physiol 1997; 272(6 Pt 1): E1008-15.
[39]
Bansal RK, Goldsmith PC, He Y, Zaloudek CJ, Ecker JL, Riemer RK. A decline in myometrial nitric oxide synthase expression is associated with labor and delivery. J Clin Invest 1997; 99(10): 2502-8.
[40]
Yallampalli C, Garfield RE, Byam-Smith M. Nitric oxide inhibits uterine contractility during pregnancy but not during delivery. Endocrinology 1993; 133(4): 1899-902.
[41]
Yallampalli C, Izumi H, Byam-Smith M, Garfield RE. An L-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy. Am J Obstet Gynecol 1994; 170(1 Pt 1): 175-85.
[42]
Duckitt K, Thornton S, O’Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database Syst Rev 2014; 5: CD002860.
[43]
Smith GN, Walker MC, McGrath MJ. Randomised, double-blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic. Br J Obstet Gynaecol 1999; 106(7): 736-9.
[44]
Bisits A, Madsen G, Knox M, et al. The Randomized Nitric Oxide Tocolysis Trial (RNOTT) for the treatment of preterm labor. Am J Obstet Gynecol 2004; 191(3): 683-90.
[45]
Lees CC, Lojacono A, Thompson C, et al. Glyceryl trinitrate and ritodrine in tocolysis: An international multicenter randomized study. GTN Preterm Labour Investigation Group. Obstet Gynecol 1999; 94(3): 403-8.
[46]
Huszar G, Roberts JM. Biochemistry and pharmacology of the myometrium and labor: regulation at the cellular and molecular levels. Am J Obstet Gynecol 1982; 142(2): 225-37.
[47]
Anotayanonth S, Subhedar NV, Garner P, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004; (4): CD004352.
[48]
Chawanpaiboon S, Laopaiboon M, Lumbiganon P, Sangkomkamhang US, Dowswell T. Terbutaline pump maintenance therapy after threatened preterm labour for reducing adverse neonatal outcomes. Cochrane Database Syst Rev 2014; (3): CD010800.
[49]
Lamont RFFN. . The role of infection in the pathogenesis of preterm labour.Progress in obstetrics and gynaecology 10 1993. 135-58.
[50]
Hudgens DR, Conradi SE. Sudden death associated with terbutaline sulfate administration. Am J Obstet Gynecol 1993; 169(1): 120-1.
[51]
MacLennan FM, Thomson MA, Rankin R, Terry PB, Adey GD. Fatal pulmonary oedema associated with the use of ritodrine in pregnancy. Case report. Br J Obstet Gynaecol 1985; 92(7): 703-5.
[52]
Page IJ, Atalla A, Young K. Fatal pulmonary oedema associated with the use of ritodrine in pregnancy. Br J Obstet Gynaecol 1986; 93(2): 197.
[53]
Taslimi MM, Sibai BM, Amon E, Taslimi CK, Herrick CN. A national survey on preterm labor. Am J Obstet Gynecol 1989; 160(6): 1352-7.
[54]
Bernstein IM, Catalano PM. Ketoacidosis in pregnancy associated with the parenteral administration of terbutaline and betamethasone. A case report. J Reprod Med 1990; 35(8): 818-20.
[55]
Halpren EW, Soifer NE, Haenel LC, Manara LR, Belsky DH. Ketoacidosis secondary to oral ritodrine use in a gestational diabetic patient: report of a case. J Am Osteopath Assoc 1988; 88(2): 241-4.
[56]
Schilthuis MS, Aarnoudse JG. Fetal death associated with severe ritodrine induced ketoacidosis. Lancet 1980; 1(8178): 1145.
[57]
Tibaldi JM, Lorber DL, Nerenberg A. Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: A case report. Am J Obstet Gynecol 1990; 163(2): 509-10.
[58]
Braden GL, von Oeyen PT, Germain MJ, Watson DJ, Haag BL. Ritodrine- and terbutaline-induced hypokalemia in preterm labor: mechanisms and consequences. Kidney Int 1997; 51(6): 1867-75.
[59]
Smith SR, Kendall MJ. Metabolic responses to beta 2 stimulants. J R Coll Physicians Lond 1984; 18(3): 190-4.
[60]
Smith SK, Thompson D. The effect of intravenous salbutamol upon plasma and urinary potassium during premature labour. Br J Obstet Gynaecol 1977; 84(5): 344-7.
[61]
Cano A, Tovar I, Parrilla JJ, Abad L. Metabolic disturbances during intravenous use of ritodrine: increased insulin levels and hypokalemia. Obstet Gynecol 1985; 65(3): 356-60.
[62]
Hurlbert BJ, Edelman JD, David K. Serum potassium levels during and after terbutaline. Anesth Analg 1981; 60(10): 723-5.
[63]
Moravec MA, Hurlbert BJ. Hypokalemia associated with terbutaline administration in obstetrical patients. Anesth Analg 1980; 59(12): 917-20.
[64]
Kuczkowski KM, Benumof JL. Rebound hyperkalemia after cessation of intravenous tocolytic therapy with terbutaline in the treatment of preterm labor: Anesthetic implications. J Clin Anesth 2003; 15(5): 357-8.
[65]
Kotani N, Kushikata T, Hashimoto H, Muraoka M, Tonosaki M, Matsuki A. Rebound perioperative hyperkalemia in six patients after cessation of ritodrine for premature labor. Anesth Analg 2001; 93(3): 709-11.
[66]
Valenzuela GJ, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000; 182(5): 1184-90.
[67]
Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2014; 2: CD004352.
[68]
Gokay Z, Ozcan T, Copel JA. Changes in fetal hemodynamics with ritodrine tocolysis. Ultrasound Obstet Gynecol 2001; 18(1): 44-6.
[69]
Gemelli M, De Luca F, Manganaro R, et al. Transient electrocardiographic changes suggesting myocardial ischaemia in newborn infants following tocolysis with beta-sympathomimetics. Eur J Pediatr 1990; 149(10): 730-3.
[70]
Kurtoglu S, Akcakus M, Keskin M, Ozcan A, Hussain K. Severe hyperinsulinaemic hypoglycaemia in a baby born to a mother taking oral ritodrine therapy for preterm labour. Horm Res 2005; 64(2): 61-3.
[71]
Mitchell BF, Olson DM. Prostaglandin endoperoxide H synthase inhibitors and other tocolytics in preterm labour. Prostaglandins Leukot Essent Fatty Acids 2004; 70(2): 167-87.
[72]
King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005; (2): CD001992.
[73]
Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: A randomised placebo-controlled trial. Br J Obstet Gynaecol 1999; 106(5): 467-73.
[74]
Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med 1984; 12(1): 25-9.
[75]
Reinebrant HE, Pileggi-Castro C, Romero CL, et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2015; (6): CD001992.
[76]
ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol 2012; 119(6): 1308-17.
[77]
Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. Am J Obstet Gynecol 2003; 188(4): 1046-51.
[78]
Eronen M, Pesonen E, Kurki T, Teramo K, Ylikorkala O, Hallman M. Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. J Pediatr 1994; 124(5 Pt 1): 782-8.
[79]
Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329(22): 1602-7.
[80]
Souter D, Harding J, McCowan L, O’Donnell C, McLeay E, Baxendale H. Antenatal indomethacin--adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998; 38(1): 11-6.
[81]
Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: A systematic review with meta-analysis. Obstet Gynecol 2005; 106(1): 173-9.
[82]
Hammers AL, Sanchez-Ramos L, Kaunitz AM. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: A systematic review with metaanalysis American journal of obstetrics and gynecology 2015. 212(4): 505 e1-13.2015;
[83]
Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: A meta-analysis and decision analysis. Obstet Gynecol 2009; 113(3): 585-94.
[84]
Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 97(2): 122-40.
[85]
Read MD, Wellby DE. The use of a calcium antagonist (nifedipine) to suppress preterm labour. Br J Obstet Gynaecol 1986; 93(9): 933-7.
[86]
Bracero LA, Leikin E, Kirshenbaum N, Tejani N. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Am J Perinatol 1991; 8(6): 365-9.
[87]
Ferguson JE II, Dyson DC, Schutz T, Stevenson DK. A comparison of tocolysis with nifedipine or ritodrine: Analysis of efficacy and maternal, fetal, and neonatal outcome. Am J Obstet Gynecol 1990; 163(1 Pt 1): 105-11.
[88]
Garcia-Velasco JA, Gonzalez Gonzalez A. A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. Int J Gynaecol Obstet 1998; 61(3): 239-44.
[89]
Janky E, Leng JJ, Cormier PH, Salamon R, Meynard J. A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. J Gynecol Obstet Biol Reprod 1990; 19(4): 478-82.
[90]
Koks CA, Brolmann HA, de Kleine MJ, Manger PA. A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. Eur J Obstet Gynecol Reprod Biol 1998; 77(2): 171-6.
[91]
Kupferminc M, Lessing JB, Yaron Y, Peyser MR. Nifedipine versus ritodrine for suppression of preterm labour. Br J Obstet Gynaecol 1993; 100(12): 1090-4.
[92]
Papatsonis DN, Van Geijn HP, Ader HJ, Lange FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labor: A randomized multicenter trial. Obstet Gynecol 1997; 90(2): 230-4.
[93]
Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: A randomized study. Am J Obstet Gynecol 1993; 169(4): 960-4.
[94]
Haghighi L. Prevention of preterm delivery: nifedipine or magnesium sulfate. Int J Gynaecol Obstet 1999; 66(3): 297-8.
[95]
Smith CS, Woodland MB. Clinical comparison of oral nifedipine and subcutaneous terbutaline for initial tocolysis. Am J Perinatol 1993; 10(4): 280-4.
[96]
Weerakul W, Chittacharoen A, Suthutvoravut S. Nifedipine versus terbutaline in management of preterm labor. Int J Gynaecol Obstet 2002; 76(3): 311-3.
[97]
Are IBH. A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology 2008; 23(2): 61-4.
[98]
Flenady V, Wojcieszek AM, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev 2014; 6: CD002255.
[99]
King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2003; (1): CD002255.
[100]
Oei SG, Mol BW, de Kleine MJ, Brolmann HA. Nifedipine versus ritodrine for suppression of preterm labor; a meta-analysis. Acta Obstet Gynecol Scand 1999; 78(9): 783-8.
[101]
Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: A meta-analysis. Obstet Gynecol 2001; 97(5 Pt 2): 840-7.
[102]
Kam KY, Lamont RF. Developments in the pharmacotherapeutic management of spontaneous preterm labor. Expert Opin Pharmacother 2008; 9(7): 1153-68.
[103]
Lamont RF, Khan KS, Beattie B, et al. The quality of nifedipine studies used to assess tocolytic efficacy: A systematic review. J Perinat Med 2005; 33(4): 287-95.
[104]
Naik Gaunekar N, Raman P, Bain E, Crowther CA. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (10): CD004071.
[105]
Vaast P, Dubreucq-Fossaert S, Houfflin-Debarge V, et al. Acute pulmonary oedema during nicardipine therapy for premature labour; Report of five cases. Eur J Obstet Gynecol Reprod Biol 2004; 113(1): 98-9.
[106]
Oei SG, Oei SK, Brolmann HA. Myocardial infarction during nifedipine therapy for preterm labor. N Engl J Med 1999; 340(2): 154.
[107]
Hodges R, Barkehall-Thomas A, Tippett C. Maternal hypoxia associated with nifedipine for threatened preterm labour. BJOG 2004; 111(4): 380-1.
[108]
Bal L, Thierry S, Brocas E, Adam M, Van de Louw A, Tenaillon A. Pulmonary edema induced by calcium-channel blockade for tocolysis. Anesth Analg 2004; 99(3): 910-1.
[109]
Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100(10): 959-61.
[110]
van Veen AJ, Pelinck MJ, van Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005; 112(4): 509-10.
[111]
Johnson KA, Mason GC. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005; 112(11): 1583.
[112]
Kandysamy V, Thomson AJ. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005; 112(11): 1583-4.
[113]
Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. BJOG 2006; 113(7): 844-5.
[114]
Verhaert D, Van Acker R. Acute myocardial infarction during pregnancy. Acta Cardiol 2004; 59(3): 331-9.
[115]
Economy KE, Abuhamad AZ. Calcium channel blockers as tocolytics. Semin Perinatol 2001; 25(5): 264-71.
[116]
Scholz H. Pharmacological aspects of calcium channel blockers Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy . 1997. 10(Suppl 3): 869-72.
[117]
Grzesiak M, Ahmed RB, Wilczynski J. 48-hours administration of nifedipine in spontaneous preterm labor - Doppler blood flow assessment of placental and fetal circulation. Neuroendocrinol Lett 2013; 34(7): 687-92.
[118]
Khan K, Zamora J, Lamont RF, et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: A systematic review and meta-regression analysis. J Mat-Fet Neonat Med 2010; 23(9): 1030-8.
[119]
Yamasato K, Burlingame J, Kaneshiro B. Hemodynamic effects of nifedipine tocolysis. J Obstet Gynaecol Res 2015; 41(1): 17-22.
[120]
Tocolysis for Women in Preterm Labour. RCOG Green–top Guideline No 1b 2011; 2011.
[121]
Thornton J. The drugs we deserve. BJOG 2003; 110(11): 969-70.
[122]
Houtzager BA, Hogendoorn SM, Papatsonis DN, et al. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006; 113(3): 324-31.
[123]
van Vliet E, Dijkema GH, Schuit E, et al. Nifedipine maintenance tocolysis and perinatal outcome: An individual participant data meta-analysis. BJOG 2016; 123(11): 1753-60.
[124]
Fuchs AR, Fuchs F, Husslein P, Soloff MS, Fernstrom MJ. Oxytocin receptors and human parturition: A dual role for oxytocin in the initiation of labor. Science 1982; 215(4538): 1396-8.
[125]
Lamont RFKK. Atosiban as a tocolytic for the treatment of spontaneous preterm labour. Expert Rev Obstet Gynecol. Expert Rev Obstet Gynecol 2008; 3(2): 163-74.
[126]
Fuchs AR, Husslein P, Fuchs F. Oxytocin and the initiation of human parturition. II. Stimulation of prostaglandin production in human decidua by oxytocin. Am J Obstet Gynecol 1981; 141(6): 694-7.
[127]
Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at parturition. J Reprod Fertil Suppl 1992; 45: 97-111.
[128]
Lundin S, Akerlund M, Fagerstrom PO, Hauksson A, Melin P. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. Acta Endocrinol (Copenh) 1986; 112(4): 465-72.
[129]
Akerlund M, Stromberg P, Hauksson A, et al. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. Br J Obstet Gynaecol 1987; 94(11): 1040-4.
[130]
Andersen LF, Lyndrup J, Akerlund M, Melin P. Oxytocin receptor blockade: A new principle in the treatment of preterm labor? Am J Perinatol 1989; 6(2): 196-9.
[131]
Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol 1995; 173(3 Pt 1): 913-7.
[132]
Goodwin TM, Paul R, Silver H, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994; 170(2): 474-8.
[133]
Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy GW, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol 1996; 13(3): 143-6.
[134]
Goodwin TM, Valenzuela GJ, Silver H, Creasy G. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group. Obstet Gynecol 1996; 88(3): 331-6.
[135]
Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182(5): 1173-83.
[136]
Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005; (3): Cd004452.
[137]
Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001; 108(2): 133-42.
[138]
Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: A multicenter effectiveness and safety study. Am J Obstet Gynecol 2000; 182(5): 1191-9.
[139]
Cabrol DGJ, Madelenat P. Treatment of preterm labor with the oxytocin antagonist atosiban: A double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001; 98(2): 177-85.
[140]
The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet Gynecol Scand 2001; 80(5): 413-22.
[141]
Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2014; 6: CD004452.
[142]
Ervin MG, Ross MG, Leake RD, Fisher DA. V1- and V2-receptor contributions to ovine fetal renal and cardiovascular responses to vasopressin. Am J Physiol 1992; 262(4 Pt 2): R636-43.
[143]
Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1995; 172(4 Pt 1): 1304-6.
[144]
Lamont RFGP. Anti-oxytocic tocolytic agents.The yearbook of obstetrics and gynaecology 2002. 130-40.
[145]
Lamont RF. Commentary: A case of non-cardiogenic lung edema in a woman treated with atosiban for preterm labor. J Perinat Med 2008; 36(5): 458-9.
[146]
Thornton S, Miller H, Valenzuela G, et al. Treatment of spontaneous preterm labour with retosiban: A phase 2 proof-of-concept study. Br J Clin Pharmacol 2015; 80(4): 740-9.
[147]
Thornton S, Valenzuela G, Baidoo C, et al. Treatment of spontaneous preterm labour with retosiban: A phase II pilot dose-ranging study. Br J Clin Pharmacol 2017; 83(10): 2283-91.
[148]
Greig PC, Massmann GA, Demarest KT, Weglein RC, Holland ML, Figueroa JP. Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. Am J Obstet Gynecol 1993; 169(4): 897-902.
[149]
Friedlander E, Feldstein O, Mankuta D, et al. Social impairments among children perinatally exposed to oxytocin or oxytocin receptor antagonist. Early Hum Dev 2017; 106-107: 13-8.
[150]
Lamont RF, Jorgensen JS. Oxytocin-receptor antagonists in the aetiology of autism spectrum disorder. Early Hum Dev 2017; 112: 60-1.
[151]
Haas DM, Morgan AM, Deans SJ, Schubert FP. Ethanol for preventing preterm birth in threatened preterm labor. Cochrane Database Syst Rev 2015; (11): CD011445.
[152]
Su LL, Samuel M, Chong YS. Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev 2014; (1): CD006770.
[153]
Martinez de Tejada B, Karolinski A, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG 2015; 122(1): 80-91.
[154]
Norwitz ER. Author's reply: To PMID 25209926. BJOG. 2015. 122(3): 447-8.
[155]
Hernandez WR, Francisco RPV, Bittar RE, Gomez UT, Zugaib M, Brizot ML. Effect of vaginal progesterone in tocolytic therapy during preterm labor in twin pregnancies: Secondary analysis of a placebo-controlled randomized trial. J Obstet Gynaecol Res 2017; 43(10): 1536-42.
[156]
Pohl O, Perks D, Rhodes J, Comotto L, Baldrick P, Chollet A. Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats. Reprod Sci 2016; 23(4): 439-47.
[157]
Pohl O, Chollet A, Kim SH, et al. OBE022, an Oral and Selective Prostaglandin F2alpha Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. J Pharmacol Exp Ther 2018; 366(2): 349-64.
[158]
Boyle AK, Rinaldi SF, Rossi AG, Saunders PTK, Norman JE. Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models. FASEB J 2019; 33(2): 2743-58.
[159]
Manuck TA. Refining Pharmacologic Research to Prevent and Treat Spontaneous Preterm Birth. Front Pharmacol 2017; 8: 118.
[160]
Paul JW, Hua S, Ilicic M, et al. Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor American journal of obstetrics and gynecology 2017. 216(3): 283 e1-e14.
[161]
Refuerzo JS, Leonard F, Bulayeva N, et al. Uterus-targeted liposomes for preterm labor management: studies in pregnant mice. Sci Rep 2016; 6: 34710.
[162]
de Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338: b744.
[163]
Kamat S, Veena P, Rani R. Comparison of nifedipine and progesterone for maintenance tocolysis after arrested preterm labour. J Obstet Gynaecol 2014; 34(4): 322-5.
[164]
Xiao C, Gangal M, Abenhaim HA. Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. J Perinat Med 2014; 42(5): 585-9.
[165]
King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2002; (2): CD002255.
[166]
Coomarasamy A, Knox EM, Gee H, Song F, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: A meta-analysis with an indirect comparison of randomised trials. BJOG 2003; 110(12): 1045-9.
[167]
van Vliet EO, Nijman TA, Schuit E, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): A multicentre, randomised controlled trial. Lancet 2016.
[168]
Mol BWJ. VVEOG, Oudijk M.A. Nifedipine versus atosiban for tocolysis in preterm labour (assessment of perinatal outcome after specific tocolysis in early labour: Apostel III-trial). J Paediatr Child Health 2015; 51(35): 1034-4810.
[169]
Nijman TAJ, Goedhart MM, Naaktgeboren CN, et al. Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial. Ultrasound Obstet Gynecol 2018; 51(6): 806-12.
[170]
Rezk M, Sayyed T, Masood A, Dawood R. Nicorandil vs nifedipine for the treatment of preterm labour: A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2015; 195: 27-30.
[171]
Downey LJ, Martin AJ. Ritodrine in the treatment of preterm labour: A study of 213 patients. Br J Obstet Gynaecol 1983; 90(11): 1046-53.
[172]
Husslein P, Roura LC, Dudenhausen J, et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG 2006; 113(Suppl. 3): 105-10.
[173]
Wex J, Connolly M, Rath W. Atosiban versus betamimetics in the treatment of preterm labour in Germany: An economic evaluation. BMC Pregnancy Childbirth 2009; 9: 23.
[174]
Wex J, Abou-Setta AM, Clerici G, Di Renzo GC. Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects. Eur J Obstet Gynecol Reprod Biol 2011; 157(2): 128-35.
[175]
Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2000; (2): CD000065.
[176]
Dehaene I, Bergman L, Turtiainen P, Ridout A, Mol BW, Lorthe E. Maintaining and repeating tocolysis: A reflection on evidence. Semin Perinatol 2017; 41(8): 468-76.
[177]
Institute of M. Preterm Birth. Causes, Consequences, and Prevention 2006 [updated 2009/12/16/]. Available from: http://www. marchofdimes.com/prematurity/index_about_10734.asp

Rights & Permissions Print Cite
Article Metrics
151
24
2
2
World Health Day
© 2024 Bentham Science Publishers | Privacy Policy